| 29.51 -0.37 (-1.24%) | 03-13 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 37.36 | 1-year : | 43.64 |
| Resists | First : | 31.98 | Second : | 37.36 |
| Pivot price | 29.36  |
|||
| Supports | First : | 26.02 | Second : | 22.32 |
| MAs | MA(5) : | 30.5 |
MA(20) : | 27.79 |
| MA(100) : | 26.35 |
MA(250) : | 23.55 |
|
| MACD | MACD : | 1.3  |
Signal : | 1.2 |
| %K %D | K(14,3) : | 80 |
D(3) : | 85.7 |
| RSI | RSI(14): 58 |
|||
| 52-week | High : | 31.98 | Low : | 14.39 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ CLDX ] has closed below upper band by 48.2%. Bollinger Bands are 61.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 12 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 30.96 - 31.13 | 31.13 - 31.27 |
| Low: | 28.97 - 29.18 | 29.18 - 29.35 |
| Close: | 29.2 - 29.51 | 29.51 - 29.77 |
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. The company has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. Celldex Therapeutics, Inc. was incorporated in 1983 and is headquartered in Hampton, New Jersey.
Sun, 15 Mar 2026
Assessing Celldex Therapeutics (CLDX) Valuation After Recent Share Price Momentum - simplywall.st
Sun, 15 Mar 2026
Eventide Asset Management LLC Has $48.10 Million Stock Holdings in Celldex Therapeutics, Inc. $CLDX - MarketBeat
Sat, 14 Mar 2026
Celldex Therapeutics (CLDX) Stock Analysis Report | Ratings, Financials & Performance - Benzinga Japan
Fri, 13 Mar 2026
Celldex Therapeutics (CLDX) Is Up 5.7% After New Phase 2 Barzolvolimab Data in Inducible Urticaria - Sahm
Tue, 10 Mar 2026
CLDX: Barzolvolimab shows strong efficacy in CSU, with key phase 3 data expected in Q4 - TradingView
Sun, 08 Mar 2026
A Look At Celldex Therapeutics (CLDX) Valuation After New Barzolvolimab Urticaria Data - Sahm
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 67 (M) |
| Held by Insiders | 6.042e+007 (%) |
| Held by Institutions | 0.2 (%) |
| Shares Short | 9,030 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.8399e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -72 % |
| Return on Assets (ttm) | 27.2 % |
| Return on Equity (ttm) | -26.2 % |
| Qtrly Rev. Growth | 1.54e+006 % |
| Gross Profit (p.s.) | -71.2 |
| Sales Per Share | -32.24 |
| EBITDA (p.s.) | -1.93278e+008 |
| Qtrly Earnings Growth | -4 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -211 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.92 |
| Price to Cash Flow | 4.69 |
| Dividend | 0 |
| Forward Dividend | 9.18e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|